XML 89 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net Revenues [Member] | Not Designated as Hedging Instrument [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax $ 16,887 $ 18,271 [1] $ 21,853 [1]
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax [2] 14 (4)  
Financial expenses [Member] | Not Designated as Hedging Instrument [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax 822 959 [1] 895 [1]
Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax [3] $ (51) $ (12) $ 82
[1] Comparative figures are based on prior hedge accounting standard.
[2] Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on revenues and expenses recorded in euro, the British pound, the Russian ruble and some other currencies during the quarter for which such instruments are purchased. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as economic hedge. These derivative instruments are recognized on the Balance Sheet at their fair value, with changes in the fair value recognized under the same line item in the Statements of Income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated Statements of Cash Flows.
[3] Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses—net.